Drug Profile
NC 2700
Alternative Names: NC-2700Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Nippon Chemiphar
- Developer J-Pharma; Nippon Chemiphar
- Class Antigouts; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hyperuricaemia
Highest Development Phases
- No development reported Gout; Hyperuricaemia
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Gout in Japan
- 28 Dec 2021 No recent reports of development identified for preclinical development in Hyperuricaemia in Japan
- 19 Oct 2018 Pharmacodynamics data from a preclinical trial in Hyperuricaemia presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting